Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent

Abstract

Extracellular vesicles (EVs) derived from mesenchymal stem cells are promising nanotherapeutics in liver diseases due to their regenerative and immunomodulatory properties. Nevertheless, a concern has been raised regarding the rapid clearance of exogenous EVs by phagocytic cells. Here we explore the impact of protein corona on EVs derived from two culturing conditions in which specific proteins acquired from media were simultaneously adsorbed on the EV surface. Additionally, by incubating EVs with serum, simulating protein corona formation upon systemic delivery, further resolved protein corona–EV complex patterns were investigated. Our findings reveal the potential influences of corona composition on EVs under in vitro conditions and their in vivo kinetics. Our data suggest that bound albumin creates an EV signature that can retarget EVs from hepatic macrophages. This results in markedly improved cellular uptake by hepatocytes, liver sinusoidal endothelial cells and hepatic stellate cells. This phenomenon can be applied as a camouflage strategy by precoating EVs with albumin to fabricate the albumin-enriched protein corona–EV complex, enhancing non-phagocytic uptake in the liver. This work addresses a critical challenge facing intravenously administered EVs for liver therapy by tailoring the protein corona–EV complex for liver cell targeting and immune evasion.

References 65

1. 1.

   Asrani SK, et al. Burden of liver diseases in the world. J. Hepatol. 2019;70:151-171.

   Not in our library10.1016/j.jhep.2018.09.014

2. 2.

   Kwak KA, et al. Current perspectives regarding stem cell-based therapy for liver cirrhosis. Can. J. Gastroenterol. Hepatol. 2018;2018:4197857.

   Not in our library10.1155/2018/4197857

3. 3.

   Guo Y, et al. Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis. J. Zhejiang Univ. Sci. B. 2016;17:831-841.

   Not in our library10.1631/jzus.b1600101

4. 4.

   Zagoura DS, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut. 2012;61:894-906.

   Not in our library10.1136/gutjnl-2011-300908

5. 5.

   Li T, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845-854.

   Not in our library10.1089/scd.2012.0395

6. 6.

   Hyun J, et al. MicroRNA125b-mediated Hedgehog signaling influences liver regeneration by chorionic plate-derived mesenchymal stem cells. Sci. Rep. 2015;5:14135.

   Not in our library10.1038/srep14135

7. 7.
   Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models · 2014

   No notice
8. 8.
   Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure · 2017

   No notice
9. 9.

   Bottger R, et al. Lipid-based nanoparticle technologies for liver targeting. Adv. Drug Deliv. Rev. 2020;154-155:79-101.

   Not in our library10.1016/j.addr.2020.06.017

10. 10.

    Lázaro-Ibáñez E, et al. Selection of fluorescent, bioluminescent, and radioactive tracers to accurately reflect extracellular vesicle biodistribution in vivo. ACS Nano. 2021;15:3212-3227.

    Not in our library10.1021/acsnano.0c09873

11. 11.
    Membrane Radiolabelling of Exosomes for Comparative Biodistribution Analysis in Immunocompetent and Immunodeficient Mice - A Novel and Universal Approach · 2019

    No notice
12. 12.

    Xiao Q, et al. The effects of protein corona on in vivo fate of nanocarriers. Adv. Drug Deliv. Rev. 2022;186:114356.

    Not in our library10.1016/j.addr.2022.114356

13. 13.
    In vivo Protein Corona Formation: Characterizations, Effects on Engineered Nanoparticles’ Biobehaviors, and Applications · 2021

    Not checked
14. 14.

    Heidarzadeh M, et al. Protein corona and exosomes: new challenges and prospects. Cell Commun. Signal. 2023;21:64.

    Not in our library10.1186/s12964-023-01089-1

15. 15.

    Faruqu FN, et al. Defined serum-free three-dimensional culture of umbilical cord-derived mesenchymal stem cells yields exosomes that promote fibroblast proliferation and migration in vitro. FASEB J. 2021;35:e21206.

    Not in our library10.1096/fj.202001768rr

16. 16.
    How pure are your vesicles? · 2013

    No notice
17. 17.

    Ramirez MI, et al. Technical challenges of working with extracellular vesicles. Nanoscale. 2018;10:881-906.

    Not in our library10.1039/c7nr08360b

18. 18.

    Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226-1232.

    Not in our library10.1016/j.cell.2016.01.043

19. 19.

    Jønson L, et al. Molecular composition of IMP1 ribonucleoprotein granules. Mol. Cell Proteom. 2007;6:798-811.

    Not in our library10.1074/mcp.m600346-mcp200

20. 20.

    Schroeder HW, Cavacini L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 2010;125:S41-S52.

    Not in our library10.1016/j.jaci.2009.09.046

21. 21.

    Cougot N, Babajko S, Séraphin B. Cytoplasmic foci are sites of mRNA decay in human cells. J. Cell Biol. 2004;165:31-40.

    Not in our library10.1083/jcb.200309008

22. 22.

    Chari A, et al. An assembly chaperone collaborates with the SMN complex to generate spliceosomal SnRNPs. Cell. 2008;135:497-509.

    Not in our library10.1016/j.cell.2008.09.020

23. 23.

    Sunesson L, Hellman U, Larsson C. Protein kinase cepsilon binds peripherin and induces its aggregation, which is accompanied by apoptosis of neuroblastoma cells. J. Biol. Chem. 2008;283:16653-16664.

    Not in our library10.1074/jbc.m710436200

24. 24.

    van Asbeck EC, et al. Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells. BMC Microbiol. 2008;8:229.

    Not in our library10.1186/1471-2180-8-229

25. 25.

    Takahashi K, et al. Relative roles of complement factor 3 and mannose-binding lectin in host defense against infection. Infect. Immun. 2005;73:8188-8193.

    Not in our library10.1128/iai.73.12.8188-8193.2005

26. 26.
    The ambiguous role of mannose-binding lectin (MBL) in human immunity · 2021

    Not checked
27. 27.
    Formation of a protein corona on the surface of extracellular vesicles in blood plasma · 2021

    Not checked
28. 28.

    Gomes FG, et al. Synergy of human platelet-derived extracellular vesicles with secretome proteins promotes regenerative functions. Biomedicines. 2022;10:238.

    Not in our library10.3390/biomedicines10020238

29. 29.
    A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation · 2022

    No notice
30. 30.

    Churchman AH, et al. Serum albumin enhances the membrane activity of ZnO nanoparticles. Chem. Commun. (Camb.). 2013;49:4172-4174.

    Not in our library10.1039/c3cc37871c

31. 31.

    Rastogi L, Kora AJ, J A. Highly stable, protein capped gold nanoparticles as effective drug delivery vehicles for amino-glycosidic antibiotics. Mater. Sci. Eng. C. 2012;32:1571-1577.

    Not in our library10.1016/j.msec.2012.04.044

32. 32.

    Zaloga J, et al. Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility. Int J. Nanomed. 2014;9:4847-4866.

    Not in our library10.2147/ijn.s68539

33. 33.

    Vauthier C, Lindner P, Cabane B. Configuration of bovine serum albumin adsorbed on polymer particles with grafted dextran corona. Colloids Surf. B. 2009;69:207-215.

    Not in our library10.1016/j.colsurfb.2008.11.017

34. 34.

    Qi J, et al. Nanoparticles with dextran/chitosan shell and BSA/chitosan core–doxorubicin loading and delivery. Int. J. Pharm. 2010;393:176-184.

    Not in our library10.1016/j.ijpharm.2010.03.063

35. 35.

    Li Z, et al. Insight into the preformed albumin corona on in vitro and in vivo performances of albumin-selective nanoparticles. Asian J. Pharm. Sci. 2019;14:52-62.

    Not in our library10.1016/j.ajps.2018.07.002

36. 36.

    Nigam P, et al. Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. J. Mater. Chem. B. 2014;2:3190-3195.

    Not in our library10.1039/c4tb00015c

37. 37.

    Peng Q, et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials. 2013;34:8521-8530.

    Not in our library10.1016/j.biomaterials.2013.07.102

38. 38.

    Takeuchi T, et al. Molecularly imprinted nanogels acquire stealth in situ by cloaking themselves with native dysopsonic proteins. Angew. Chem. Int. Ed. 2017;56:7088-7092.

    Not in our library10.1002/anie.201700647

39. 39.

    Albrecht C, et al. Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen–albumin conjugate. J. Drug Target. 1998;6:105-117.

    Not in our library10.3109/10611869808997886

40. 40.

    Kamps JAAM, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc. Natl Acad. Sci. USA. 1997;94:11681-11685.

    Not in our library10.1073/pnas.94.21.11681

Cited by papers we hold 2

• Improved Accessibility of Extracellular Vesicle Surface Molecules Upon Partial Removal of the Protein Corona by High Ionic Strength · 2025
  Not checked
• Dendritic Cell Derived‐Extracellular Vesicles Engineered to Express Interleukin‐12 and Anti‐CTLA‐4 on Their Surface for Combinational Cancer Immunotherapy · 2025
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.